Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
I think she used it in the context of trial leads, clinicians and the like. In other words, when people like Christian Ottensmeier, Poulam Patel and so on start seeing first hand what Scib can do, they spread the word and effectively, they lead clinical opinion. If these key opinion leaders are impressed, then it must be really good, is the thinking, other oncologists start taking note and hopefully, so does Big Pharma!
For the benefit of occasional BB readers, let me put the 'RIP personalised medicines' claim into context. This was simply the conclusion of one speaker in a 'this house believes...' debate. The other side, by definition, believes the opposite to be true. See slide below.
https://twitter.com/livHeadandNeck/status/1725543598177837348?t=lrCGNacG1MX1ORuqfq67CA&s=19
Research note from Turner Pope:
https://mailchi.mp/turnerpope.com/ironveld-plc-research-note-11214099?e=ba1847ebf6
Hi Burble. I'd normally suggest contacting Consilium for clarification but I am still waiting for even an acknowledgement of several emails and calls on the patent expiry date confusion caused by the last RNS. Why do they even bother putting their contact details on an RNS if they are not going to respond??
Of the five patients that had reached the week 19 imaging timepoint, all five patients showed a sustained reduction in the overall tumour burden and this durability of response was also seen
in four patients reaching week 25 and two reaching week 37 imaging timepoints. In the two patients that had reached week 37
the shrinkage was between -87 and -94%. The responders at week 13 are ongoing with their study treatment and will be observed for
the total study period of 2 years.
Reassuringly, the addition of the SCIB1 to the standard of care Ipilimumab with nivolumab did not enhance the toxicity of the Checkpoint combination therapy in the patients evaluated to date.
When SCIB1 was included to the standard of care regimen of ipilimumab with nivolumab, the overall size of metastatic melanoma lesions had reduced significantly in 9/11 patients,
yielding a RECIST 1.1 overall response rate of 82%. Due to the target of 9 responses being achieved earlier than expected, the study advanced to the second stage of Simon and non-futility was
declared. Of the two patients that did not achieve a RECIST 1.1 response, 1 patient had progressive disease within 7 weeks of entering the study and the other patient had a decrease of -24.1%
of their target lesions at 13 weeks (a RECIST 1.1 SD).
This patient is currently ongoing with their study treatment . In stage 2, an additional 18 responders are required in a maximum of 32 patients
but based on the current data the probability of success is expected to be ~90%. Cohort 2 is ongoing.
No worries Berm. It was just an idle question as I don't know my way round that site, but as far as I can see, they update every Wednesday around 13.00 GMT? As today's publications seemed to relate to patents lodged up to 14th September, I was surmising whether SCLP's latest ( lodged on 17/9) is likely to appear in full next week?
Morning Bankfool.
In answer to your question about how companies that don't make a profit are valued, AZs investment in Cellectis today may give some clues. (Cellectis is a US stock with shares trading yesterday at around $0.97 and a market cap of $54m):
In Q4 2023, Cellectis will receive an initial payment of $105m from AstraZeneca, which comprises a $25m upfront cash payment under the terms of a research collaboration agreement and an $80m equity investment.
The initial equity investment of $80m, at $5/share, represents an equity stake of c. 22% in Cellectis. A further $140m equity investment, at $5/share, is expected to close in early 2024 subject to the signing of a final binding agreement following completion of a consultation with the Cellectis employee representative bodies and customary closing conditions including Cellectis shareholders' approval and regulatory clearances. Post-closing of this second investment, AstraZeneca will hold a total equity stake of c. 44% in Cellectis. AstraZeneca expects to treat its investment in Cellectis as an associate.
Under the terms of the research collaboration, Cellectis is also eligible to receive an investigational new drug (IND) option fee and development, regulatory and sales-related milestone payments, ranging from $70m up to $220m, per each of the 10 candidate products, plus tiered royalties.
Abstract number 1533
Session date and time Friday, Nov. 3, 2023, 9am - 7pm EDT
Location Exhibit Halls A and B1 - San Diego Convention Center
A copy of the poster will be available on Scancell's website following the conference at: https://www.scancell.co.uk/vaccine-publications